• Skip to primary navigation
  • Skip to main content
  • Skip to footer
Call Text Chat Email Refer a Patient Join a Study

Search

Hide Search
MotherToBaby

MotherToBaby

Medications and More during pregnancy and breastfeeding

Shopping Cart
Show SearchSearch
  • About
    • Our Work
    • Our Team
    • About OTIS
    • OTIS Membership
    • In Your Area
    • Our Partners
    • Our Impact
    • Member Recognition
  • Exposures
    • Pregnancy and Breastfeeding Exposures
    • Fact Sheets
    • Baby Blogs
    • Podcasts
    • Webinars
    • Interactive Tool
    • Infographics
    • LactRx App
  • Studies
    • Ongoing Studies
    • What’s Involved?
    • Join Now
    • Refer a Patient
    • Health Providers
    • Pharma Industry
    • Publications
  • Health Professionals
    • Patient Education and Provider Resources
    • Refer a Patient
    • Request Materials
    • Annual Meeting
    • Exhibiting Schedule
    • FAQs
    • OTIS Membership
  • Media
    • Media Requests
    • Press Releases
    • eNews Sign Up
  • Donate
  • Contact
  • Show SearchSearch

Duloxetine (Cymbalta®)

March 1, 2026

Selected References

  • Ankarfeldt MZ, et al. 2021. Exposure to duloxetine during pregnancy and risk of congenital malformations and stillbirth: A nationwide cohort study in Denmark and Sweden. PLOS Medicine, 18(11):e1003851. 
  • Ankarfeldt MZ, et al. 2023. Duloxetine exposure during pregnancy and the risk of offspring being born small for gestational age or prematurely: A nationwide Danish and Sweden safety study. Drugs Real World Outcomes, 10(1):69-81. 
  • Bellantuono C, et al. 2015. The safety of serotonin-noradrenaline reuptake inhibitors (SNRIs) in pregnancy and breastfeeding: a comprehensive review.  Hum Psychopharmacol,  30(3):143-51. 
  • Gentile S, et al. 2019. Managing fibromyalgia syndrome in pregnancy no bridges between USA and EU. Archives of Women’s Mental Health, 22(6):711-721.   
  • Hoog SL, et al. 2013. Duloxetine and pregnancy outcomes: safety surveillance findings. International Journal of Medical Sciences. 10(4):413-419. 
  • Huybrechts KF, et al. 2020 Maternal and fetal outcomes following exposure to duloxetine in pregnancy: cohort study. BMJ 368:m237. 
  • Kallen B, et al. 2013. The use of central nervous system active drugs during pregnancy. Pharmaceuticals. 6(10):1221-1286. 
  • Kjaersgaard MI, et al. 2013. Prenatal antidepressant exposure and risk of spontaneous abortion – a population-based study. PLoS One, 8(8):e72095. 
  • Lassen D, et al. 2016. First-Trimester Pregnancy Exposure to Venlafaxine or Duloxetine and Risk of Major Congenital Malformations: A Systematic Review. Basic & clinical pharmacology & toxicology. 118(1):32-6. doi:10.1111/bcpt.12497. 
  • Liu D, et al. 2025. Uncovering safety signals of duloxetine: Real-world evidence from the FAERS database. J Affect Disord. 388:119517. doi:10.1016/j.jad.2025.119517 
  • Marks C, et al. 2021.Comparing newborn outcomes after prenatal exposure to individual antidepressants: a retrospective cohort study. Pharmacotherapy 41(11):907-914. 
  • Punjani N, et al. 2021. Impact of duloxetine on male fertility: A randomized controlled clinical trial. Andrologia, 53(10):e14207. 
  • Richendrfer H, et al. 2018. Cluster analysis profiling of behaviors in zebrafish larvae treated with antidepressants and pesticides. Neurotoxicology Teratology, 69:54-62.  

Footer

               

Hot Links

  • Home
  • Exposures
  • Fact Sheets
  • Baby Blogs
  • Podcasts
  • Pregnancy Studies
  • Join a Study Now
  • Healthcare Professionals
  • Refer a Patient
  • Request Materials
  • News
  • Donate
  • Ask An Expert

Current Studies

  • Ankylosing Spondylitis
  • Eczema (Moderate-to-Severe)/Atopic Dermatitis
  • Hidradenitis Suppurativa
  • Lupus
  • Multiple Sclerosis
  • Non-Radiographic Axial Spondyloarthritis
  • Psoriasis
  • Psoriatic Arthritis

Contact

Exposure Information Service
866.626.6847

Pregnancy Studies
877.311.8972

Media Inquiries
619.368.3259
nchavez@mothertobaby.org

MotherToBaby, a service of the Organization of Teratology Information Specialists

Copyright © 2026 The Organization of Teratology Information Specialists

  • Accessibility
  • Privacy
  • Terms
  • Site Map
^

This website is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling $1,200,000 with zero percentage financed with non-governmental sources. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, HRSA, HHS, or the U.S. Government.